The FDA's Fast Lane Covered 22 Drugs in 17 Months, Then Went Dark — and the 'Permanent FDA Moat' Was Never Structural

The FDA's own programme is not dead; it has stopped issuing new vouchers without cancelling what is already in flight. Since Commissioner Marty Makary resigned on May 12, 2026, no new national priority voucher has been awarded, and the executive council of political appointees that vetted those files has gone dormant. Companies inside the programme say FDA leadership told them the agency is not moving forward even as applications stay open — one company said submissions simply \"don't advance.\" Nine drugs are still inside the programme and roughly a dozen of the original 22 have been approved, five of them after May, so the freeze bites on new awards rather than on files already running.

The cause is structural, and it is the same reason the September-era bull case for American regulatory speed was mis-specified. A commissioner's programme has no statute behind it, and its gatekeepers were political appointees answering to one administration. When the people running it left, the gate closed with them, and nobody with the standing to reopen it currently holds the post. The statutory programme is built differently: Congress reauthorized the rare pediatric disease priority review voucher through Sept 30, 2029 on Feb 3, 2026, with transferability written in, so paper keeps minting on approvals regardless of who holds the White House.

Two things did not happen. Approval throughput did not slow: CDER's 2026 novel drug list stood at 48 by early November against 46 for the whole of 2025. And the nine files still inside the programme were not abandoned; career scientists simply resumed owning their timelines. The shelf is an allocation decision, not a capacity decision — which is precisely why it can be reversed by one appointment.

Speed was never a moat; it was a subsidy. The free lane compressed reviews to one or two months for 22 drugs across 17 months, and every holder of that compression kept the benefit. The durable version is priced and tradeable: a rare pediatric disease voucher cuts a standard review from about ten months to about six, and 2026 transactions cleared at $155 million to $210 million each. That works out at roughly $39 million to $53 million for every month of faster review — a figure the market set, not the agency.

What survived is the legislated half, and it is thriving. The rare pediatric disease voucher is transferable, can be redeemed against a different product, and runs to Sept 30, 2029; the Federal Register notice for Ultragenyx's Genglycos confirms the mint still working after the shelf. The arithmetic favours patience over optimism: Ultragenyx sold two of these in October for $413 million gross, about $350 million net, against $401 million of cash and marketable securities at Sept 30 and a market value near $1.70 billion.

Upstream of the paperwork sit the rarest assets in biotech. Ultragenyx earned two vouchers from two gene therapy approvals in a single quarter, Jazz Pharmaceuticals sold one for $200 million in January, and Cyprium, the majority-owned subsidiary of Fortress Biotech, closed a $205 million sale in March. Each transaction converts a regulatory event into non-dilutive cash, which is why the voucher market kept functioning after the commissioner's programme stopped issuing paper.

Here is where the shelf actually bites. With no new free ultra-fast reviews to promise a partner, and with the statutory voucher that can be bought only after an approval has already happened, the cash-versus-milestone split in biotech deals re-prices. Instruments that pay at approval become scarcer and dearer; instruments that pay on sales rather than on approval dates become the marginal funding rail for anyone who needs to keep funding a launch.

That makes Royalty Pharma the marginal buyer of biotech cash, on trailing revenue of $2.62 billion and EBITDA of $1.55 billion, against $8.59 billion of total debt and $545 million of cash and short-term investments. It paid Revolution Medicines $250 million in May 2026 for additional royalty rights, with up to $1.5 billion of committed flexible capital still contingent on milestones, and added a $100 million rusfertide agreement with Zealand Pharma in August. Capital that used to wait for an approval now gets paid for approval risk directly.

European pharma has spent years pressing for American-style review speed, and its own trade association's diagnosis points somewhere else. EFPIA's April 2025 analysis of why medicines arrive late in Europe put the fix with the Commission and the EMA: cut the scientific evaluation period from 210 days to 180 and hold the 46 days from CHMP opinion to final decision. That is a competent, incremental copy of a review clock. But the binding constraint EFPIA documents is not the review — it is pricing and reimbursement, where Bulgaria updates its positive list once a year, Hungary and Croatia do it ad hoc, and a medicine approved on schedule can still wait years for a price. The advantage Europe was told to copy runs on pricing freedom, not the review clock, and that is the thing Europe is actually negotiating against.

The FDA's own behaviour reinforces the point. Its statutory voucher buys roughly four months; its free lane bought ten to eleven and is now closed; and the Europeans were offered a 30-day shave on a 210-day clock. If the fastest review lane in the world is worth less than the access and pricing layer beneath it, then a thesis built on the stopwatch was measuring the wrong instrument — and now that the stopwatch has been withdrawn, the instrument that still works is the one Europe was already fighting over.